Bristol Still Committed To Yervoy In Prostate Cancer, Despite Phase III Failure
This article was originally published in The Pink Sheet Daily
Yervoy misses overall survival endpoint in Phase III castration-resistant prostate cancer study, but it does show activity, particularly in patients with less advanced disease.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.